BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 10597318)

  • 1. Inhibition of growth of human malignant glioblastoma in nude mice by antagonists of bombesin/gastrin-releasing peptide.
    Kiaris H; Schally AV; Sun B; Armatis P; Groot K
    Oncogene; 1999 Nov; 18(50):7168-73. PubMed ID: 10597318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatostatin analogues and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of human glioblastomas in vitro and in vivo.
    Pinski J; Schally AV; Halmos G; Szepeshazi K; Groot K
    Cancer Res; 1994 Nov; 54(22):5895-901. PubMed ID: 7954420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of growth of OV-1063 human epithelial ovarian cancers and c- jun and c- fos oncogene expression by bombesin antagonists.
    Chatzistamou I; Schally AV; Sun B; Armatis P; Szepeshazi K
    Br J Cancer; 2000 Oct; 83(7):906-13. PubMed ID: 10970693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
    Stangelberger A; Schally AV; Varga JL; Hammann BD; Groot K; Halmos G; Cai RZ; Zarandi M
    Prostate; 2005 Aug; 64(3):303-15. PubMed ID: 15754342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice.
    Stangelberger A; Schally AV; Varga JL; Zarandi M; Szepeshazi K; Armatis P; Halmos G
    Clin Cancer Res; 2005 Jan; 11(1):49-57. PubMed ID: 15671527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitory effect of bombesin receptor antagonist RC-3095 on the growth of human pancreatic cancer cells in vivo and in vitro.
    Qin Y; Ertl T; Cai RZ; Halmos G; Schally AV
    Cancer Res; 1994 Feb; 54(4):1035-41. PubMed ID: 8313359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitory effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 on the growth of the androgen-independent Dunning R-3327-AT-1 rat prostate cancer.
    Pinski J; Reile H; Halmos G; Groot K; Schally AV
    Cancer Res; 1994 Jan; 54(1):169-74. PubMed ID: 7903203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antagonists of bombesin/gastrin-releasing peptide decrease the expression of angiogenic and anti-apoptotic factors in human glioblastoma.
    Kanashiro CA; Schally AV; Cai RZ; Halmos G
    Anticancer Drugs; 2005 Feb; 16(2):159-65. PubMed ID: 15655413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bombesin antagonists inhibit growth of MDA-MB-435 estrogen-independent breast cancers and decrease the expression of the ErbB-2/HER-2 oncoprotein and c-jun and c-fos oncogenes.
    Bajo AM; Schally AV; Krupa M; Hebert F; Groot K; Szepeshazi K
    Proc Natl Acad Sci U S A; 2002 Mar; 99(6):3836-41. PubMed ID: 11891317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A potent bombesin receptor antagonist inhibits bombesin-stimulated growth of mouse colon cancer cells in vitro: absence of autocrine effects.
    Narayan S; Spindel ER; Rubin NH; Singh P
    Cell Growth Differ; 1992 Feb; 3(2):111-8. PubMed ID: 1323998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Powerful inhibition of in-vivo growth of experimental hepatic cancers by bombesin/gastrin-releasing peptide antagonist RC-3940-II.
    Szepeshazi K; Schally AV; Rick FG; Block NL; Vidaurre I; Halmos G; Szalontay L
    Anticancer Drugs; 2012 Oct; 23(9):906-13. PubMed ID: 22926257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of growth of HT-29 human colon cancer xenografts in nude mice by treatment with bombesin/gastrin releasing peptide antagonist (RC-3095).
    Radulovic S; Miller G; Schally AV
    Cancer Res; 1991 Nov; 51(21):6006-9. PubMed ID: 1682040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice.
    Pinski J; Schally AV; Halmos G; Szepeshazi K; Groot K; O'Byrne K; Cai RZ
    Br J Cancer; 1994 Nov; 70(5):886-92. PubMed ID: 7947094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted cytotoxic analogue of bombesin/gastrin-releasing peptide inhibits the growth of H-69 human small-cell lung carcinoma in nude mice.
    Kiaris H; Schally AV; Nagy A; Sun B; Armatis P; Szepeshazi K
    Br J Cancer; 1999 Nov; 81(6):966-71. PubMed ID: 10576652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II inhibit tumor growth and decrease the levels and mRNA expression of epidermal growth factor receptors in H-69 small cell lung carcinoma.
    Koppán M; Halmos G; Arencibia JM; Lamharzi N; Schally AV
    Cancer; 1998 Oct; 83(7):1335-43. PubMed ID: 9762934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumoral activity of bombesin analogues on small cell lung cancer xenografts: relationship with bombesin receptor expression.
    Thomas F; Arvelo F; Antoine E; Jacrot M; Poupon MF
    Cancer Res; 1992 Sep; 52(18):4872-7. PubMed ID: 1325285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective inhibition of experimental human ovarian cancers with a targeted cytotoxic bombesin analogue AN-215.
    Engel JB; Keller G; Schally AV; Halmos G; Hammann B; Nagy A
    Clin Cancer Res; 2005 Mar; 11(6):2408-15. PubMed ID: 15788692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of growth of MDA-MB-468 estrogen-independent human breast carcinoma by bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II.
    Kahán Z; Sun B; Schally AV; Arencibia JM; Cai RZ; Groot K; Halmos G
    Cancer; 2000 Mar; 88(6):1384-92. PubMed ID: 10717621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of growth of ES-2 human ovarian cancers by bombesin antagonist RC-3095, and luteinizing hormone-releasing hormone antagonist Cetrorelix.
    Chatzistamou I; Schally AV; Szepeshazi K; Groot K; Hebert F; Arencibia JM
    Cancer Lett; 2001 Sep; 171(1):37-45. PubMed ID: 11485826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stimulation by bombesin and inhibition by bombesin/gastrin-releasing peptide antagonist RC-3095 of growth of human breast cancer cell lines.
    Yano T; Pinski J; Groot K; Schally AV
    Cancer Res; 1992 Aug; 52(16):4545-7. PubMed ID: 1643647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.